文献速递细菌感染、耐药与抗菌药物医院感染防控

超越死亡率:医院获得性细菌性肺炎与呼吸机相关性细菌性肺炎的结局期望排序(DOOR)终点的开发与应用

Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
PubMed 文献 · Clin Infect Dis · 2024-01-01

研究针对耐多药菌所致的医院获得性细菌性肺炎与呼吸机相关性细菌性肺炎(HABP/VABP),由多学科委员会定制感染性疾病DOOR终点,纳入感染并发症、严重不良事件与死亡,并应用于ZEPHyR与VITAL两项随机对照试验;两项试验中DOOR显示治疗组总体临床结局相似。

要点

  • HABP/VABP的DOOR终点纳入感染并发症、严重不良事件与死亡。
  • ZEPHyR中利奈唑胺组结局优于万古霉素组的概率为50.2%(95%CI 45.1%–55.3%)。
  • VITAL中特利霉素组结局优于利奈唑胺组的概率为48.7%(95%CI 44.8%–52.6%)。

核心结论

  • HABP/VABP的DOOR终点提供了比临床试验常规呈现更细粒度的临床结局信息。
  • 作者认为HABP/VABP试验将受益于前瞻性使用DOOR。

研究设计与样本

  • 多学科委员会创建了针对HABP/VABP定制的感染性疾病DOOR终点,纳入感染并发症、严重不良事件与死亡。
  • 将该终点应用于两项既往已完成的大型随机对照试验:ZEPHyR比较万古霉素与利奈唑胺,VITAL比较利奈唑胺与特利霉素。

主要发现

  • 两项试验中,HABP/VABP的DOOR均显示治疗组间总体临床结局相似。
  • ZEPHyR中,接受利奈唑胺治疗的受试者结局优于接受万古霉素治疗受试者的概率为50.2%(95%CI 45.1%–55.3%)。
  • VITAL中,接受特利霉素治疗的受试者结局优于接受利奈唑胺治疗受试者的概率为48.7%(95%CI 44.8%–52.6%)。
  • DOOR组分分析显示,仅考虑临床应答时,接受特利霉素治疗的受试者结局劣于接受利奈唑胺治疗的受试者。
  • 肾功能下降的受试者接受特利霉素治疗时总体结局改善。

关键数值与推荐

  • ZEPHyR:利奈唑胺组结局优于万古霉素组的概率50.2%(95%CI 45.1%–55.3%)。
  • VITAL:特利霉素组结局优于利奈唑胺组的概率48.7%(95%CI 44.8%–52.6%)。

临床怎么用

  • 作者认为HABP/VABP试验将受益于前瞻性使用DOOR。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are frequently caused by multidrug-resistant organisms. Patient-centered endpoints in clinical trials are needed to develop new antibiotics for HABP/VABP. Desirability of outcome ranking (DOOR) is a paradigm for the design, analysis, and interpretation of clinical trials based on a patient-centered, benefit-risk evaluation. METHODS: A multidisciplinary committee created an infectious diseases DOOR endpoint customized for HABP/VABP, incorporating infectious complications, serious adverse events, and mortality. We applied this to 2 previously completed, large randomized controlled trials for HABP/VABP. ZEPHyR compared vancomycin to linezolid and VITAL compared linezolid to tedizolid. For each trial, we evaluated the DOOR distribution and probability, including DOOR component and partial credit analyses. We also applied DOOR in subgroup analyses. RESULTS: In both trials, the HABP/VABP DOOR demonstrated similar overall clinical outcomes between treatment groups. In ZEPHyR, the probability that a participant treated with linezolid would have a more desirable outcome than a participant treated with vancomycin was 50.2% (95% confidence interval [CI], 45.1%--55.3%). In VITAL, the probability that a participant treated with tedizolid would have a more desirable outcome than a participant treated with linezolid was 48.7% (95% CI, 44.8%-52.6%). The DOOR component analysis revealed that participants treated with tedizolid had a less desirable outcome than those treated with linezolid when considering clinical response alone. However, participants with decreased renal function had improved overall outcomes with tedizolid. CONCLUSIONS: The HABP/VABP DOOR provided more granular information about clinical outcomes than is typically presented in clinical trials. HABP/VABP trials would benefit from prospectively using DOOR.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Howard-Anderson J, Hamasaki T, Dai W, et al. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Clin Infect Dis. 2024. PMID: 37740559. doi:10.1093/cid/ciad576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。